For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Unrealized gain (loss) on marketable securities | -94 | |||
| Total other comprehensive gain (loss) | -94 | |||
| Research and development | 154,224 | |||
| General and administrative | 18,273 | |||
| Total operating expenses | 172,497 | |||
| Loss from operations | -172,497 | |||
| Other income, net | 6,824 | |||
| Net Income Loss | -165,700 | |||
| Research and development | 154,224 | |||
| General and administrative | 18,273 | |||
| Total operating expenses | 172,497 | |||
| Loss from operations | -172,497 | |||
| Other income, net | 6,824 | |||
| Net loss | -165,375 | |||
| Total comprehensive loss | -165,767 | |||
| Basic EPS | -2.27 | |||
| Diluted EPS | -2.27 | |||
| Basic Average Shares | 72,947,927 | |||
| Diluted Average Shares | 72,947,927 | |||
Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. (LRMR)